KDR and neoplasm: Depending on these promising results, and in continuation of our work for the development of new VEGFR-2 inhibitors having potent and selective anti-tumor activity, we utilized the encouraging lead compounds (VII and VIII) for the design and synthesis of a new series of quinazoline-based derivatives to act as VEGFR-2 inhibitors.